公开(公告)号：US10300067B2

公开(公告)日：2019-05-28

申请号：US15893804

申请日：2018-02-12

申请人： TAIHO PHARMACEUTICAL CO., LTD.

发明人： Kazuhisa Minamiguchi ,  Shigeo Okajima ,  Shinichi Aoki ,  Masanori Asai ,  Takahiro Asai ,  Hiroyoshi Yamanaka ,  Suguru Dohi

IPC分类号： C07D471/04 ,  A61K31/519 ,  A61K31/553 ,  A61P5/28 ,  A61K9/00 ,  A61K31/53

摘要： A method for inhibiting androgen activity, including administering an effective amount of a tetrahydropyridopyrimidine compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need thereof, and a method for treating tumor, including administering an effective amount of a tetrahydropyridopyrimidine compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need thereof

公开(公告)号：US09889136B2

公开(公告)日：2018-02-13

申请号：US15203059

申请日：2016-07-06

申请人： TAIHO PHARMACEUTICAL CO., LTD.

发明人： Kazuhisa Minamiguchi ,  Shigeo Okajima ,  Shinichi Aoki ,  Masanori Asai ,  Takahiro Asai ,  Hiroyoshi Yamanaka ,  Suguru Dohi

IPC分类号： C07D471/04 ,  A61K31/519 ,  A61K31/553 ,  A61P5/28 ,  A61P35/00 ,  A61K9/00 ,  A61K31/53

CPC分类号： A61K31/519 ,  A61K9/0019 ,  A61K31/53 ,  A61K31/553 ,  C07D471/04

摘要： A method for inhibiting androgen activity, including administering an effective amount of a tetrahydropyridopyrimidine compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need thereof, and a method for treating tumor, including administering an effective amount of a tetrahydropyridopyrimidine compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need thereof

公开(公告)号：US09662333B2

公开(公告)日：2017-05-30

申请号：US15023894

申请日：2015-05-28

申请人： TAIHO PHARMACEUTICAL CO., LTD.

发明人： Kazuhisa Minamiguchi ,  Shigeo Okajima ,  Shinichi Aoki ,  Masanori Asai ,  Takahiro Asai ,  Hiroyoshi Yamanaka ,  Suguru Dohi

IPC分类号： C07D471/04 ,  A61K31/519 ,  A61K31/553 ,  A61P5/28 ,  A61K9/00 ,  A61K31/53

CPC分类号： A61K31/519 ,  A61K9/0019 ,  A61K31/53 ,  A61K31/553 ,  C07D471/04

摘要： A tetrahydropyridopyrimidine compound represented by formula (I) or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition including the tetrahydropyridopyrimidine compound or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier:

公开(公告)号：US20160310496A1

公开(公告)日：2016-10-27

申请号：US15203059

申请日：2016-07-06

申请人： TAIHO PHARMACEUTICAL CO., LTD.

发明人： Kazuhisa MINAMIGUCHI ,  Shigeo Okajima ,  Shinichi Aoki ,  Masanori Asai ,  Takahiro Asai ,  Hiroyoshi Yamanaka ,  Suguru Dohi

IPC分类号： A61K31/519 ,  A61K31/53 ,  A61K9/00 ,  A61K31/553

CPC分类号： A61K31/519 ,  A61K9/0019 ,  A61K31/53 ,  A61K31/553 ,  C07D471/04

摘要： A method for inhibiting androgen activity, including administering an effective amount of a tetrahydropyridopyrimidine compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need thereof, and a method for treating tumor, including administering an effective amount of a tetrahydropyridopyrimidine compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need thereof

公开(公告)号：US10370372B2

公开(公告)日：2019-08-06

申请号：US15771487

申请日：2016-11-25

申请人： TAIHO PHARMACEUTICAL CO., LTD.

发明人： Kazuhisa Minamiguchi ,  Shigeo Okajima ,  Takahiro Asai ,  Masanori Asai ,  Yoshio Ogino

IPC分类号： C07D471/04 ,  C07D519/00 ,  A61K31/519 ,  A61K31/55 ,  A61P35/00

摘要： To provide a compound having an inhibitory activity for an androgen receptor. A fused pyrimidine compound represented by the following formula (I) or a pharmaceutically acceptable thereof (in the formula, X, Y, Z, R1, and R2 are as defined in the specification).